Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Letrozole + Avastin in Breast Cancer
NCT00530868Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Oct 2007
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in breast cancer (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Pathologic Complete Response at 24 weeks. Started Oct 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00530868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00530868.